Table 2. Results of univariate and multivariate regression analyses of carpal tunnel syndrome.
Univariate | Multivariate (full model) | Multivariate (reduced model) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | ||
Age at the start of the study (in 2003), years | ||||||||||
40–49 | Ref. | Ref. | Ref. | |||||||
50–59 | 1.047 | 0.994–1.103 | 0.0846 | - | - | - | - | |||
60–69 | 0.722 | 0.675–0.771 | <0.0001* | 0.590 | 0.551–0.632 | <0.0001* | 0.590 | 0.551–0.631 | <0.0001* | |
≥70 | 0.348 | 0.302–0.402 | <0.0001* | 0.312 | 0.270–0.360 | <0.0001* | 0.312 | 0.270–0.360 | <0.0001* | |
Sex | ||||||||||
Male | Ref. | Ref. | Ref. | |||||||
Female | 4.313 | 4.083–4.555 | <0.0001* | 4.431 | 4.192–4.685 | <0.0001* | 4.429 | 4.190–4.682 | <0.0001* | |
Body mass index at the start of the study (in 2003), kg/m2 | ||||||||||
<18.5 | Ref. | Ref. | Ref. | |||||||
18.5–22.9* | 1.994 | 1.544–2.447 | <0.0001* | 1.604 | 1.274–2.019 | <0.0001* | 1.604 | 1.274–2.020 | <0.0001* | |
23.0–24.9* | 2.367 | 1.880–2.981 | <0.0001* | 2.088 | 1.658–2.629 | <0.0001* | 2.089 | 1.658–2.630 | <0.0001* | |
25.0–29.9* | 2.725 | 2.167–3.428 | <0.0001* | 2.450 | 1.947–3.083 | <0.0001* | 2.451 | 1.948–3.084 | <0.0001* | |
30.0–35.0* | 3.710 | 2.884–4.771 | <0.0001* | 2.726 | 2.119–3.508 | <0.0001* | 2.728 | 2.120–3.510 | <0.0001* | |
Comorbidities | ||||||||||
Diabetes mellitus | 1.041 | 0.972–1.114 | 0.2510 | |||||||
Rheumatoid arthritis | 1.932 | 1.783–2.095 | <0.0001* | 1.540 | 1.418–1.673 | <0.0001* | 1.543 | 1.421–1.674 | <0.0001* | |
Gout | 0.888 | 0.719–1.095 | 0.2665 | - | - | - | - | |||
End-stage renal disease | 0.715 | 0.423–1.207 | 0.2090 | - | - | - | - | |||
Hypothyroidism | 1.611* | 1.346–1.928 | <0.0001* | 1.049 | 0.876–1.256 | 0.6064 | - | - | ||
Raynaud's syndrome | 2.718* | 1.543–4.787 | 0.0005* | 2.267* | 1.286–3.996 | 0.0047 | 2.273* | 1.289–4.007 | 0.0045* |
*p<0.05.
CI: confidence interval, HR: hazard ratio, Ref.: reference.